How are some people's brains able to fight off Alzheimer's disease? Why do some people have the biological signs and damage of Alzheimer's disease , but their memory and intellectual abilities do not decline? Scientists have discovered the answer to this question. Why do some people have the biological signs and damage of Alzheimer's disease, but their memory and intellectual abilities do not decline? Scientists have discovered the answer to this question. According to researchers at the Netherlands Institute for Neuroscience , a rare and special type of immature cells in the brains of such people manage to survive and fight off the damage of the disease, so they do not show symptoms of Alzheimer's. The discovery, published in the journal Cell Stem Cell , raises hopes for the development of completely new treatments to slow the progression of dementia and preserve memory. Why does Alzheimer's disease affect people differently? This has always been a great myst...
GSK's drug is 60 percent more effective in curing cancer in women
World-renowned pharmaceutical company GSK has announced that the initial results of its new drug 'Mosertatag Rezedacan', which is used to treat uterine and ovarian cancer, are encouraging.
In the first phase of clinical trials, 'Mosertatag Rezedacan' has shown success in platinum-resistant ovarian cancer by 62 percent and in uterine cancer by 67 percent.
GSK is preparing to start five large 'Phase-3' clinical trials in 2026 and the drug could change the way cancer is treated, said Hesham Abdullah.
World-renowned pharmaceutical company GSK has announced that the initial results of its new drug used to treat uterine and ovarian cancer are very encouraging.
The new antibody-drug conjugate (ADC) drug, called mosertatag rezedecan, has shown positive results in a phase 1 clinical trial.
The BEHOLD-1 study, presented at the Society of Gynecologic Oncology (SGO) annual meeting in Puerto Rico, showed significant improvements in the treatment of advanced cancer patients.
What does the study say?
The study, conducted in patients who had failed other cancer treatments, has shown very good success rates.
The drug showed an objective response rate (ORR) of up to 62 percent in patients with platinum-resistant ovarian cancer.
Similarly, the drug was successful in up to 67 percent in patients with advanced and recurrent uterine cancer.
Until now, there were only limited treatment options available for patients with such complex conditions, with very low success rates. But ‘Mosertatag rezedecan’ has been shown to be more effective because it directly targets an antigen called B7-H4 on cancer cells.
Safety and side effects
The safety aspect of the drug was also paid attention to during the study. Most patients experienced common side effects such as nausea (75 to 82 percent), anemia and fatigue. Scientists claim that the drug is safe, as serious side effects such as lung problems (interstitial lung disease) were seen in 3 percent of patients.
Five large trials to start in 2026
Following this initial success, GSK is preparing to start five large ‘phase-3’ clinical trials around the world in 2026.
According to GSK’s Global Head of Oncology Hesham Abdullah, evidence has been found that this drug could change the way cancer is treated. Millions of women worldwide are affected by uterine and ovarian cancer every year.
Seventy percent of ovarian cancer patients are diagnosed at a very late stage, while 15 to 20 percent of uterine cancer patients are diagnosed at a late stage.
In such a situation, this new drug from GSK is expected to be a lifesaver for women battling cancer.
Comments
Post a Comment
If you have any doubts. Please let me know.